Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Quantum Biopharma ( (TSE:QNTM) ) has issued an update.
On April 10, 2025, Quantum BioPharma announced a significant partnership between its licensee, Celly Nutrition, and the Asian American Trade Associations Council (AATAC) to expand the retail availability of unbuzzd, an alcohol detox beverage. This collaboration aims to increase sales and customer reach by leveraging AATAC’s extensive network of over 80,000 retail locations across the United States and Puerto Rico. The partnership is expected to enhance Quantum BioPharma’s market positioning in the health and wellness sector, particularly in the growing recovery products category.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is involved in research and development through its subsidiary, Lucid Psycheceuticals Inc., and has developed the alcohol detox beverage unbuzzd through its licensee, Celly Nutrition Corp. Quantum BioPharma retains a significant ownership stake in Celly Nutrition and holds rights to develop similar pharmaceutical products.
YTD Price Performance: 75.98%
Average Trading Volume: 2,819,504
Technical Sentiment Signal: Buy
Current Market Cap: $16.3M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.